1. Introduction {#sec1-nutrients-11-00935}
===============

In Europe, colorectal cancer (CRC) is the cancer type with both the second highest incidence and mortality rate \[[@B1-nutrients-11-00935]\]. Substantial CRC risk may derive from dietary factors, genetic variants, and their interactions \[[@B2-nutrients-11-00935],[@B3-nutrients-11-00935]\].

Experimental and observational evidence suggests that suboptimal dietary intakes of the micronutrient selenium (Se) contribute to greater risk for the development of cancers at several anatomical sites, including the colorectum \[[@B4-nutrients-11-00935],[@B5-nutrients-11-00935],[@B6-nutrients-11-00935]\]. In humans, Se exerts its potential anti-carcinogenic properties through incorporation into 25 selenoproteins by the amino acid selenocysteine \[[@B7-nutrients-11-00935],[@B8-nutrients-11-00935]\]. Several selenoproteins protect cells from damaging oxidative radicals including the glutathione peroxidases (notably GPX1 and GPX4), components of the thioredoxin reductase system (TXNRD1-3) and selenoprotein P (SELENOP; please note the modified selenoprotein nomenclature \[[@B9-nutrients-11-00935]\]) which is also critical for Se transport \[[@B8-nutrients-11-00935],[@B10-nutrients-11-00935],[@B11-nutrients-11-00935]\].

The major mechanism through which Se is thought to influence the risk of CRC development is variation in gene expression and biosynthesis of protective selenoproteins \[[@B12-nutrients-11-00935],[@B13-nutrients-11-00935]\]. In rodent models, adequate Se intake and selenoprotein expression have been shown to prevent colon cancer while selenoprotein dysregulation may increase colon cancer risk \[[@B14-nutrients-11-00935],[@B15-nutrients-11-00935],[@B16-nutrients-11-00935]\]. Data from nutritional intervention trials and epidemiological studies suggest implications for Se intake regarding CRC risk could potentially be more important in individuals with particular selenoprotein genotypes and/or in populations with low Se status, such as in Western Europe where the present study was conducted \[[@B4-nutrients-11-00935],[@B5-nutrients-11-00935],[@B17-nutrients-11-00935],[@B18-nutrients-11-00935]\]. Risk modification by sex has also been observed for CRC risk associations with selenoprotein genotypes \[[@B19-nutrients-11-00935],[@B20-nutrients-11-00935]\] and Se status \[[@B5-nutrients-11-00935],[@B17-nutrients-11-00935]\].

Genetic variations in approximately half of the 25-known human selenoprotein genes have been associated with susceptibility to CRC and/or colorectal adenoma (CRA) risk in at least seven populations from Asia, North America and Europe; in addition some of these variants have been shown to impact survival outcomes (reviewed in \[[@B4-nutrients-11-00935],[@B21-nutrients-11-00935]\]). Although some of these studies have been performed in suboptimal Se intake areas, large studies have more generally been conducted in Se-replete environments in North America and these have reported evidence both for \[[@B22-nutrients-11-00935],[@B23-nutrients-11-00935]\] and against \[[@B17-nutrients-11-00935]\] an association of selenoprotein genes with CRC risk. However, only a limited number of single nucleotide polymorphisms (SNPs) in selected selenoprotein genes have been analyzed, while in several of these reports the Se status of the analyzed cohort was not assessed.

To our knowledge, it is unknown which selenoproteins are critical in maintaining colonic health and no study has comprehensively evaluated variation in all selenoprotein genes for association with CRC risk. Moreover, interactions of selenoprotein genetic variations according to robust Se status biomarkers have not been explored. As both genetic factors and dietary Se intake can influence the pattern of selenoprotein expression and biosynthesis, we hypothesized that variation in selenoprotein genes, and in related signaling pathway genes influenced by Se intake (together comprising the 'Se pathway'), affect CRC development risk, while Se status may modify this risk.

In this study, we have examined for the first time the association of detailed Se pathway gene variation with cancer risk in 1420 CRC cases and 1421 controls within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. We previously reported in a subset of this nested cohort with 966 case-control pairs that a higher Se status (ascertained by serum levels of Se and SELENOP) was associated with a lower CRC risk \[[@B5-nutrients-11-00935]\]. In these Western European subjects, the mean Se and SELENOP circulating levels were 84.0 μg/L and 4.3 mg/L in cases and 85.6 μg/L and 4.4 mg/L in controls, respectively. Thus, our present study was conducted in a generally suboptimal Se status population, as these Se concentrations are insufficient for optimal GPX3 expression and SELENOP saturation \[[@B5-nutrients-11-00935],[@B6-nutrients-11-00935]\]. We now report the interaction between these genes and their corresponding pathways with Se status biomarkers and CRC risk.

2. Materials and Methods {#sec2-nutrients-11-00935}
========================

2.1. Study Population and Design {#sec2dot1-nutrients-11-00935}
--------------------------------

EPIC is a multicenter prospective cohort study designed to investigate the association between diet, lifestyle, genetic and environmental factors and the incidence of cancers. The rationale and methods of the EPIC design have been described previously \[[@B24-nutrients-11-00935],[@B25-nutrients-11-00935]\]. Briefly, 521,448 men and women mostly aged 25--70 years were enrolled between 1992--2000 in 23 sub-cohorts in 10 European countries (Denmark, France, Germany, Greece, Italy, The Netherlands, Norway, Spain, Sweden, and United Kingdom). The present analysis is based on participant data from all sub-cohorts except for Norway. At recruitment, standardized dietary, lifestyle and socio-demographic questionnaires including information on physical activity, education, smoking and medical history; anthropometric data, and blood samples were collected from participants. Blood and DNA samples are stored at the International Agency for Research on Cancer (IARC, Lyon, France) at −196 °C under liquid nitrogen for all countries except Denmark (−150 °C, nitrogen vapor) and Sweden (−80 °C freezers). Sample storage standardization including DNA extraction and quantification protocols were previously described in \[[@B26-nutrients-11-00935]\].

All study participants provided written informed consent. Ethical approval for the EPIC study was obtained from the review boards of the IARC (IARC Ethics Committee) and local participating centers. Study design methods were performed in accordance with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines (<https://www.strobe-statement.org/index.php?id=strobe-home>).

2.2. Follow-Up for Cancer Incidence {#sec2dot2-nutrients-11-00935}
-----------------------------------

Cancer incidence was determined through record linkage with population-based cancer registries (Denmark, Italy, Netherlands, Spain, Sweden, United Kingdom) or via a combination of methods, including the use of health insurance records, cancer and pathology registries, and active contact of study subjects or next-of-kin (France, Germany, Greece). Complete follow-up censoring dates for this study varied among centers, ranging between June 2002 and June 2003.

2.3. Selection of Cases and Controls and Study Design {#sec2dot3-nutrients-11-00935}
-----------------------------------------------------

Case subjects were men and women who developed first incident CRC after recruitment and before the latest follow-up date. Cancer incidence data were coded using the 10th Revision of the International Classification of Diseases (ICD-10) and the second revision of the International Classification of Disease for Oncology (ICDO-2). Colon cancers were defined as tumors in the cecum, appendix, ascending colon, hepatic flexure, transverse colon, splenic flexure, descending and sigmoid colon (C18.0-C18.7), and overlapping or unspecified origin tumors (C18.8 and C18.9). Rectal cancers were defined as tumors occurring at the recto-sigmoid junction (C19) or rectum (C20). Anal canal cancers (C21) were excluded. Colorectal cancer is the combination of the colon and rectal cancer cases.

All subjects with prior cancer diagnosis at any site (except non-melanoma skin cancer) were excluded. Cases were matched 1:1 by study center of enrollment, sex, age at blood collection, time of blood collection and fasting status, and menopausal status among women. Premenopausal women were matched on phase of menstrual cycle and postmenopausal women were matched on current hormonal therapy (HT) use. The matching was done as part of a previously published study on Se status \[[@B5-nutrients-11-00935]\], except for cases from Denmark for which new control subjects were identified due to problems with accessing the biobank. Furthermore, additional newly identified cases with their matching controls were also included for the genotyping from all participating countries but did not have biomarkers of Se status. Sweden was the only country of the nine participating in the genetic analysis for which we had no Se status data. Hence, there were 1478 cases and 1478 controls available for genotyping but the Se status information was only available for 966 of the cases and for 966 of the controls.

2.4. Gene Selection and Rationale {#sec2dot4-nutrients-11-00935}
---------------------------------

To examine selenoprotein gene and wider Se pathway gene variations in relation to CRC risk, we selected 1264 functional and haplotype tagging SNPs (tagSNPs) to comprehensively analyze common SNP variation in 164 Se pathway genes, which we assigned into eight functional pathways (listed in [Supplementary Table S1](#app1-nutrients-11-00935){ref-type="app"}). These included 42 genes in the primary selenoprotein pathway 1 (25 selenoprotein genes and 17 genes involved in Se transport and metabolism), and 122 genes in pathways 2--8 from (i) pathways affected by Se intake (Wnt, mTOR, Nrf2 and NF-κB signaling, endoplasmic reticulum and oxidative stress responses), and (ii) associated pathways of inflammatory response, apoptosis, DNA repair, Transforming growth factor (TGF) beta-signaling, and cell-cycle control \[[@B12-nutrients-11-00935]\] as detailed in Méplan and Hesketh, 2012 \[[@B13-nutrients-11-00935]\]. Variants in several genes from these affiliated pathways have been associated with CRC risk including regions of the Wingless/Integrated (Wnt) signaling gene *C-MYC* in CRC genome-wide association studies (GWAS) \[[@B27-nutrients-11-00935]\]. Our SNP analysis set was substantially enlarged from and included the 384 Se pathway SNPs (in 72 Se related genes) Se 'SNP-Chip' devised for a similar study of gene-Se interaction in a prostate cancer study within EPIC \[[@B28-nutrients-11-00935]\].

2.5. Tagging Single Nucleotide Polymorphism (tagSNP) Selection Protocol {#sec2dot5-nutrients-11-00935}
-----------------------------------------------------------------------

A list of SNPs in all gene regions was compiled using the data from HapMap (release 27, based on dbSNP version b126 and NCBI genome build 36). TagSNPs were selected by use of the Tagger algorithm as implemented in the Haploview 3.2 software (Broad Institute, Cambridge, MA, USA). Parameters used for SNP selection were a Minor Allele Frequency (MAF) ≥5% in Caucasians and pairwise tagging (r^2^ ≥ 0.8). To include SNPs in promoter and potential regulatory regions, +/− 2 to 5 kilo base-pairs beyond the 5′ and 3′ ends were included. Additionally, known functional variants in our selected genes were added to the tagSNP list, e.g., for the selenoproteins these included rs7579, rs297299, and rs3877899 in *SELENOP* \[[@B4-nutrients-11-00935]\]. Selected SNPs were then assessed for suitability for the *Illumina GoldenGate^TM^* (Saffron Walden, Essex, UK) genotyping platform using Illumina's custom assay building platform (<https://www.illumina.com/Documents/products/technotes/technote_goldengate_design.pdf>). Fifty-five SNPs which failed assay development criteria were replaced by proxy SNPs, i.e., those within the same genic region in high LD (r^2^ \> 0.8) to the original SNP. Proxy SNP replacements for functional selenoprotein SNPs which failed assay design included rs1800668 for *GPX1*-rs1050450, and rs5845 plus rs540049 for *SELENOF*-rs5859. However, there were no adequate proxies for *SELENOS*-rs34713741 or *GPX4*-rs713041.

2.6. Genotyping {#sec2dot6-nutrients-11-00935}
---------------

A total of 1264 SNPs from 164 Se pathway genes were genotyped by *Illumina Goldengate^TM^* in DNA samples available for 1478 case-control pairs matched within EPIC. Genotyping was performed simultaneously for cases and controls, blinded to case-control status (but with matched pairs analyzed in the same batch). A total of 62 replicate samples were genotyped to test for internal quality control, approximately 2 per genotyping plate, with the lowest reproducibility frequency for each of the replicates of 0.98. Samples with unclear or failed genotype calls were excluded from the analysis, leaving 1420 cases and 1421 controls for subsequent analyses.

From the 1264 initially selected, 96 SNPs failed genotyping, 27 failed Hardy--Weinberg Equilibrium (HWE), and 101 had less than 80% successfully genotyped samples. Thus, 1040 SNPs in 154 Genes (24 selenoprotein genes analyzed of 25, and 130 other Se pathways genes) with at least 80% genotypes across all genotyped samples were included in the final dataset (with a final genotyping call rate of 0.97, excluding zero call rate and those removed). [Supplementary Table S2](#app1-nutrients-11-00935){ref-type="app"} provides the full gene and SNP list successfully analyzed in the current study.

2.7. Selenium Status Assays {#sec2dot7-nutrients-11-00935}
---------------------------

Measurements of serum Se and SELENOP were previously done for a subset (966 cases and 966 controls) of the current analyzed cohort. The methods used were described in Hughes et al., 2015 and Hybsier et al., 2017 \[[@B5-nutrients-11-00935],[@B29-nutrients-11-00935]\]. Briefly, total Se levels were measured in 4 uL of each serum sample using a bench-top total reflection X-ray fluorescence (TXRF) spectrometer (Picofox^TM^ S2, Bruker Nano GmbH, Berlin, Germany). SELENOP protein concentrations were ascertained from 20 μL of each serum sample by a colorimetric enzyme-linked immunoassay (Selenotest™, ICI GmbH, Berlin, Germany). For quality-control, the sample type (case or control) was blinded and two serum samples of known Se and SELENOP concentrations for intra-assay variability were included in each analysis plate. The samples were measured in duplicate and the mean concentration values, standard deviation (SD), and coefficient of variation (CV) were calculated. Duplicate samples with variances in concentration over 10% were re-measured. The evaluation was performed using GraphPad Prism 6.01 (GraphPad Software, La Jolla, CA, USA) using a four-parameter logistic function. The CV was 7.3% and 7.2% for controls 1 (SELENOP: 1.5 mg/L) and 2 (SELENOP: 8.6 mg/L), respectively.

2.8. Statistical Analysis {#sec2dot8-nutrients-11-00935}
-------------------------

Both unconditional and conditional logistic regression analysis were carried out to assess the association of individual SNPs with CRC risk, adjusting for age (as a continuous variable), sex, and study center and provided similar results. We present the data for the unconditional logistic regression. Four standard genetic analysis models were tested for disease penetrance: multiplicative, additive, common recessive, and common dominant models \[[@B30-nutrients-11-00935]\]. Sub-group analyses by sex and anatomical sub-site of the colorectum (colon and rectum) were conducted. The associations between Se and SELENOP concentrations and genetic variants (coded as 0, 1, 2 corresponding to the number of minor alleles) were assessed among controls using linear regression models adjusted for age, sex, and center. Further adjustment by body mass index (BMI), smoking status, and physical activity did not change the results substantially.

Multiple testing corrections were performed by the Benjamini--Hochberg (BH) procedure \[[@B31-nutrients-11-00935]\]. *P*-values were also adjusted for correlated tests (*P*~ACT~) to take account of the correlated nature of the SNP data in biologically relevant and related pathways \[[@B32-nutrients-11-00935]\]. BH was performed for all SNPs, followed by *P*~ACT~ for the genes that had SNPs with *P* \< 0.01.

We further employed exploratory gene- and pathway-based testing based on overall SNP variation to help identify possible important Se related biological pathways and genes with multiple risk variants that may be discounted in multiple testing corrections for the large number of SNPs with small effect sizes in a SNP by SNP approach. Genes were classified a priori into a primary best-known functional pathway based on the literature (listed in [Supplementary Table S1](#app1-nutrients-11-00935){ref-type="app"}). Gene- and pathway-based *P*-values were computed using the PIGE (Self-Contained Gene Set Analysis for Gene- and Pathway-Environment Interaction Analysis) R package which implements the modified Adaptive Rank Truncated Product (ARTP) test using a permutation algorithm \[[@B33-nutrients-11-00935]\] to accommodate gene-environment interactions (<https://cran.rproject.org/web/packages/PIGE/index.html>). Prior to this analysis, SNPs in high linkage disequilibrium (LD) were removed using AdaJoint \[[@B34-nutrients-11-00935]\] and the online tool SNPsnap (<https://data.broadinstitute.org/mpg/snpsnap/about.html>) so that all SNP pairs had LD r^2^ \< 0.8. Gene x Se status interactions were also examined using the PIGE R package. Although these methods do not identify individual susceptibility loci, they may help to identify a pathway that could modify the association between Se status and CRC risk. An advantage is that they do not require a priori knowledge of directionality for the variants.

All statistical tests were two-sided, and *P*-values \< 0.05 were considered statistically significant (except *P* \< 0.1 for *P*~ACT~). Analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC, USA) and R (R Foundation for Statistical Computing, Vienna, Austria; <http://www.R-project.org/>) statistical packages.

3. Results {#sec3-nutrients-11-00935}
==========

3.1. Baseline Characteristics of Participants {#sec3dot1-nutrients-11-00935}
---------------------------------------------

The baseline characteristics of participants are presented in [Table 1](#nutrients-11-00935-t001){ref-type="table"}. Colon and rectal cancer cases were diagnosed, on average, 4.1 and 4.2 years after blood collection, respectively. CRC cases were overall less likely to be physically active compared to controls. There were no data on Se supplement use for our study participants.

3.2. Se Pathway Genetic Variation and Colorectal Cancer (CRC) Risk Association {#sec3dot2-nutrients-11-00935}
------------------------------------------------------------------------------

The 1040 tagging SNPs successfully analyzed from 154 genes and in HWE are shown in [Supplementary Table S2](#app1-nutrients-11-00935){ref-type="app"} (which also provides all the genetic analysis results for CRC, plus stratified analyses for colon and rectal sub-site and by sex). These include 325 SNPs from 41 selenoprotein and Se transport/selenoprotein biosynthesis genes (designated as the primary Se pathway 1), and 715 variants from the other 113 wider Se metabolic pathway genes (pathways 2--8). A summary of the genetic associations before and after multiple testing corrections is provided in [Supplementary Figure S1](#app1-nutrients-11-00935){ref-type="app"}. Prior to adjustment for multiple comparisons, there were 144 SNPs in 63 genes nominally associated with CRC risk (*P* \< 0.05 in at least one of the disease penetrance models tested; listed in [Supplementary Table S3](#app1-nutrients-11-00935){ref-type="app"}). There were 28 unique SNPs in LD with other associated SNPs and these are listed and highlighted in [Supplementary Table S3](#app1-nutrients-11-00935){ref-type="app"} (tab 'LD CEU'). Among the 40 SNPs significantly associated with CRC risk from pathway 1, approximately half (21) were in 12 selenoprotein genes (i.e., 50% of the 24 selenoprotein genes successfully genotyped out of 25) and have the potential to affect the function or expression of individual selenoproteins, although this remains to be investigated. These 12 selenoprotein genes include those previously found associated with CRC risk (*GPX1, GPX4, SELENOF, TXNRD1, TXNRD2, TXNRD3*; for reviews, see \[[@B4-nutrients-11-00935],[@B21-nutrients-11-00935]\]) and several with limited prior or no previous evidence of association with CRC risk (*DI01, GPX6, SELENOM, SELENON, SELENOT, SELENOV*). The other 19 SNPs associated with CRC in pathway 1 are in 8 of the 17 (47%) other Se transport /selenoprotein biosynthesis genes. Therefore, they have the potential to affect the synthesis of most selenoproteins (which also needs to be examined). Notably, 31% of the genes harboring SNPs associated with CRC risk (20 of 63) were related to selenoprotein biosynthesis and function implicated in protection from cancer development \[[@B4-nutrients-11-00935],[@B21-nutrients-11-00935]\] with pathway 1 and 2 proteins involved in (1) Se homeostasis (*SELENOP, SEPHS1, SEPSEC*, *EFSEC, SCLY*), (2) antioxidant enzymes (*GPXs, TXNRDs, SELENON*), and (3) endoplasmic reticulum (ER) function or stress (*SELENOF, SELENOM, SELENOT*, and again *SELENON*). Additionally, several of these genes (e.g., *GPX1, GPX5, LRP2, SEPHS1, SELENOM, SELENON, TXNRD1*, and *TXNRD2*) had multiple SNPs and/or SNPs with raw *P*-values \< 0.01 associated with CRC risk further supporting a role of selenoproteins, selenoprotein metabolism, ER stress, and oxidative stress in CRC development. [Table 2](#nutrients-11-00935-t002){ref-type="table"} lists the SNPs in the primary Se pathway 1 with raw *P*-values \< 0.01 associated with CRC risk.

In pathways 3--8, considering genes with multiple SNPs associated with CRC risk or SNPs with raw *P*-values \< 0.01 for at least one genetic model, there were several notable and some novel associations with CRC risk for genes in pathways 3 (*C-MYC, FRZB*), 4 (*APAF1, BAX, FOXO3*), 5 (*IL12B, RPS6KA2, TRL4*), 6 (*MSH2, MSH3*) and 7 (*BMP2, BMPR2, SMAD3, SMAD7, TFGB1*).

None of the SNPs in the primary Se pathway 1 remained significant after multiple testing corrections by the BH procedure. Overall, only 6 SNPs harbored by more distantly related genes in cell-signaling pathways retained significance (*FRZB*, *SMAD3*, and *SMAD7*; see [Table 3](#nutrients-11-00935-t003){ref-type="table"}). Genes harboring SNPs with raw *P*-values \< 0.01 with CRC risk for at least one genetic model (21 genes/34 SNPs) were further considered for gene-wide variance significance by the *P*~ACT~ method. For pathway 1, the *TXNRD1* selenoprotein variant rs11111979, an intron 3′--5′UTR SNP previously associated with healthy aging \[[@B35-nutrients-11-00935]\], remained borderline significant for an association with CRC risk (*P*~ACT~ = 0.100; *P*~ACT~ significance threshold was *P* \< 0.1) in the recessive genetic model. Including *FRZB*, *SMAD3* and *SMAD7*, the other wider pathway genes retaining significance were *C-MYC* (*P*~ACT~ = 0.032), *BMP2* (*P*~ACT~ = 0.012) and *BAX* (*P*~ACT~ = 0.035).

[Supplementary Table S3](#app1-nutrients-11-00935){ref-type="app"} also catalogs the SNPs with raw significant *P*-values and the BH corrections stratified by cancer sub-site (comprising 138 SNPs in 65 genes for colon in tab '*colon cancer*' and 123 SNPs in 54 genes for rectum listed in tab '*rectal cancer*'). Additionally, the tab '*All*' lists all the SNPs showing an association for CRC, colon only, rectal only, plus the analyses stratified by sex. Generally, there was predominate overlap in the genes associated with CRC and sub-site risks. Genes containing variants uniquely associated only with sub-site risk plus raw *P*-values \< 0.01 comprised rs12124257 in *PTGS2* for colon cancer and 4 SNPs in *IL10* for rectal cancer.

3.3. Associations Between Se Pathway Genetic Variation and Se Status {#sec3dot3-nutrients-11-00935}
--------------------------------------------------------------------

Among controls, 99 different SNPs in 55 genes were nominally associated with Se status (raw *P*-values \< 0.05). From these 99 variants, 87 SNPs from 45 genes were associated with either Se or SELENOP levels (55 SNPs in 33 genes and 56 SNPs in 37 genes, respectively) while the other 12 variants from 10 genes were associated with both Se status measures, including 2 each in *HIF1A* and *SMAC*. Eight pathway 1 genes harbored 14 SNPs significant for Se level changes (including 7 SNPs in 5 selenoprotein genes) while 9 pathway 1 genes carried 15 variants significant for SELENOP status association (11 SNPs in 6 selenoprotein genes). However, none of the associations retained significance after BH multiple testing adjustments. These SNP IDs together with the beta coefficients for change in Se (μg/L) or SELENOP (mg/L) are listed according to gene pathway in [Supplementary Table S4](#app1-nutrients-11-00935){ref-type="app"}.

3.4. Pathway Analysis {#sec3dot4-nutrients-11-00935}
---------------------

An exploratory analysis of CRC risk with gene variation and gene x Se status interaction within eight predefined pathways was performed using the PIGE package. A summary of the main PIGE results per pathway is presented in [Table 4](#nutrients-11-00935-t004){ref-type="table"}, while [Supplementary Table S5](#app1-nutrients-11-00935){ref-type="app"} provides all the *P*-values for each gene per pathway designation. Considering nominal significance for association with disease risk by pathway of *P* \< 0.05, then these analyses suggest that TGF-beta signaling (*P* \< 0.001) is the sole pathway highly associated with CRC risk independent of Se status interaction. Antioxidant/redox pathway genetic variation combined with Se status interactions was associated with a significant effect on CRC risk (*P* = 0.011 and 0.010 for Se and SELENOP interactions, respectively), possibly driven by SNPs in *HIF1A*, *KEAP1, GPX7, CAT*, and *SOD2* (when considering the *P*-values for each individual gene regarding gene only variation and gene x Se status interaction; see [Supplementary Table S5](#app1-nutrients-11-00935){ref-type="app"}). In contrast, the risk association with gene variation in the apoptosis pathway seems to depend more on interaction with Se levels *(P* = 0.003) but not with SELENOP concentrations (*P* = 0.105). For gene only analyses there were several genes across the pathways associated with CRC risk including the pathway 1 genes *GPX1, SELENOM, SELENON*, and *SEPHS1*, from which only *SELENON* was significant for both the gene only and gene x Se interaction PIGE analyses ([Supplementary Table S5](#app1-nutrients-11-00935){ref-type="app"}). In agreement with previous large gene association and GWAS studies, overall genetic variation in the *SMAD3, SMAD7, BMP2*, and *BMPR2* genes was associated with CRC risk \[[@B36-nutrients-11-00935],[@B37-nutrients-11-00935],[@B38-nutrients-11-00935]\]. Excluding individuals with no measurements of Se or SELENOP concentrations did not substantially change the main gene only PIGE results (both sets of results are provided in [Supplementary Table S5](#app1-nutrients-11-00935){ref-type="app"}).

4. Discussion {#sec4-nutrients-11-00935}
=============

The results of this prospective nested case-control study represent the largest reported analysis of both the association of Se pathway SNP variation and the interaction with Se status biomarkers (serum Se levels and SELENOP protein concentrations) with CRC risk. The analysis of 1,040 tagSNPs in 154 Se pathway genes in DNA samples from 1,420 CRC cases and 1,421 controls within EPIC indicated that 144 of these SNPs in 63 genes were nominally associated with CRC risk. However, for pathway 1 only the *TXNRD1* selenoprotein gene rs11111979 SNP retained borderline significance after correction for multiple testing. For pathways 2--8, variants in *BAX, BMP2, C-MYC, FRZB, SMAD3*, and *SMAD7* passed significance thresholds following these adjustments.

Selenoprotein genes nominally associated with CRC risk included several with limited or no prior evidence (*DIO1, GPX6, SELENOM, SELENON, SELENOT, SELENOV*) and those reported in several studies (*GPX1, GPX4, SELENOF, TXNRD1, TXNRD2, TXNRD3*) for an association with CRC (or specifically colon or rectal cancer) risk. This latter group of genes has been more extensively examined due to their putative roles related to cancer prevention in colonic tissue (for reviews, see \[[@B4-nutrients-11-00935],[@B21-nutrients-11-00935]\]), while the former group of selenoprotein genes have generally less well-characterized function, especially regarding how they may affect colorectal function and CRC development. Overall, any functional consequences from genetic variations in these genes, together with Se status, may affect several oxidative stress, inflammatory, and signal translation pathways implicated in colorectal carcinogenesis \[[@B13-nutrients-11-00935],[@B39-nutrients-11-00935]\]. Notably several of these genes are ER-resident selenoproteins (*SELENOF, SELENOM, SELENON, SELENOT*), thought to be involved in ER-stress response and calcium flux, comprising a potentially important mechanism of selenoprotein-related cancer prevention or promotion \[[@B40-nutrients-11-00935]\].

None of the 3 *GPX1* SNPs (rs17080528, rs3448, rs9818758) or rs2074451 in *GPX4* associated with CRC risk are in high LD (i.e., r^2^ ≥ 0.8) to the functional *GPX1* Pro/Leu rs1050450 and *GPX4* rs713041 SNPs (for which the *Illumina* assays failed) previously implicated in prostate, breast, lung (rs1050450), and CRC risk (rs713041) \[[@B4-nutrients-11-00935]\]. However, from these pathway 1 genes, only a *TXNRD1* selenoprotein variant (rs11111979), one of the three thioredoxin reductases which function in redox control \[[@B8-nutrients-11-00935]\], remained borderline significant for an increased CRC risk when applying gene-wide variance considerations by the *P*~ACT~ method. Interestingly, this SNP inducing a change in the 5′untranslated region of *TXNRD1*, among others in *TXNRD1*, was previously observed to be associated with age-related physical performance \[[@B35-nutrients-11-00935]\], and age is a primary risk factor for CRC development \[[@B41-nutrients-11-00935]\]. In the wider metabolic pathway, following adjustment for multiple testing, genotypes for SNPs in Wnt, TGF-beta signaling, and apoptosis pathway genes (*C-MYC, FRZB, SMAD3, SMAD7, BMP2*, and *BAX*) were also significantly associated with CRC risk.

Positive associations of selenoprotein gene variants with CRC risk have been more commonly reported in areas with suboptimal Se availability such as European populations, than regions with generally adequate Se intake (e.g., North America). However, tagSNPs in several selenoprotein genes (*GPX3, TXNRD3, SELENON, SELENOF*, and *SELENOX*) were also associated with colon or rectal cancer risk and/or survival outcomes in two separate studies of several large case-control USA cohorts drawn from populations with generally adequate dietary Se intakes \[[@B22-nutrients-11-00935],[@B23-nutrients-11-00935]\]. Associations of multiple SNPs in the same selenoprotein gene with CRC risk were observed in this study for *GPX1*, *SELENON*, *TXNRD1*, and *TXNRD2* (3, 4, 3, and 3 SNPs, respectively), broadly comparable to previous reports \[[@B4-nutrients-11-00935]\]. As reported by Slattery et al. in 2012 many of the same selenoprotein genes were separately associated with colon and rectal cancer risk in sub-site analyses although risks often differed by SNP \[[@B22-nutrients-11-00935]\]. From the 4 *SELENON* variants that were associated with CRC risk (rs11247735, rs2072749, rs4659382, and rs11247710), the first 3 were previously associated with rectal cancer risk in this North American cohort \[[@B22-nutrients-11-00935]\]. In our sub-site analyses, rs11247735, rs2072749, and rs11247710 were associated with rectal cancer risk only, and rs4659382 with both colon and rectal cancer. We also found further modifications of gene only and gene-Se risk for CRC by sex, as indicated by our previous studies of selenoprotein genetic variation in a Czech population \[[@B19-nutrients-11-00935]\] and Se status in the EPIC study \[[@B5-nutrients-11-00935]\]. This reflects the importance of interactions between Se intake, Se status and genotype, sex and CRC sub-type risks (reviewed in \[[@B4-nutrients-11-00935]\]).

Prior to this study there were few data available on the interaction of selenoprotein genotype and Se status regarding CRC risk, apart from a study in a Se replete population of North American women which reported that the null results for serum Se did not differ by selenoenzyme (*GPX1-4* and *SELENOP*) genetic variants \[[@B17-nutrients-11-00935]\]. The effect of Se pathway SNPs on the efficacy of Se utilization may be particularly relevant to CRC risk in populations with sub-optimal Se status, such as this study within EPIC \[[@B5-nutrients-11-00935]\]. We observed that numerous genetic variations were associated with Se status levels (as assessed by serum Se and SELENOP concentration), although these were not significant after adjustment for multiple tests. However, in the PIGE analysis overall gene and pathway genetic variation interacted with biomarkers of Se status to alter CRC risk. As expected, there were several variations in pathway 1 nominally associated with Se status levels. These included selenoprotein genes *SELENON*, *SELENOP*, *SELENOS*, and *TXNRD1* that are regulated by Se availability and whose genetic variations have been previously shown to affect blood and tissue Se levels \[[@B6-nutrients-11-00935],[@B21-nutrients-11-00935],[@B42-nutrients-11-00935],[@B43-nutrients-11-00935]\]. Transgenic mouse studies underlined the critical function of SELENOP for Se organification and transport \[[@B11-nutrients-11-00935]\]. Thus, SNP interactions with SELENOP levels may be particularly important regarding CRC risk as serum SELENOP is a functional marker of Se status and is more associated with CRC risk than Se in this cohort \[[@B5-nutrients-11-00935]\]. Notably, all 4 of the variants associated with both SELENOP status and CRC risk in the SNP only analysis were from 2 selenoprotein genes; rs4659382, rs11247710, and rs2072749 in *SELENON* and the *P*~ACT~ borderline significant rs11111979 variant in *TXNRD1*. Selenoproteins SELENOP, SELENON, and TXNRD1 are antioxidant enzymes and their genetic variations plus regulation by SELENOP levels may be important factors in relation to colorectal carcinogenesis. We observed an association of SELENOP levels with rs6413428 in *SELENOP*, which in a SNP-only analysis was previously observed to be associated with CRC risk in the USA \[[@B44-nutrients-11-00935]\], an area of generally high Se status, but not in our study. Another *SELENOP* variant, rs3877899, was also associated with SELENOP status, while the GG genotype for this SNP previously showed the highest significant correlation of all selenoprotein genotypes tested between serum Se and activity of the vital antioxidant enzyme thioredoxin reductase \[[@B45-nutrients-11-00935]\]. This latter study also showed a correlation between serum Se and increased DNA damage with *SELENOS*-rs4965373 under peroxide challenge. We selected rs12910524 in *SELENOS* as a proxy tagSNP for this variant (as rs4965373 failed *Illumina* assay development) and found that it was significantly associated with Se levels. The lipoprotein megalin receptor (LRP2) protein appears to mediate SELENOP uptake to various tissues and affect plasma Se status levels \[[@B46-nutrients-11-00935],[@B47-nutrients-11-00935]\]. Here, the *LRP2* SNPs rs12614394, rs2229266, rs2389557, rs700552, and rs9789747 were associated with CRC risk alone while the rs3755166 promoter SNP was associated with Se levels. Previously, rs3755166 has been associated with Alzheimer's disease with the rare allele showing decreased transcriptional activity \[[@B48-nutrients-11-00935]\]. Intriguingly, this indicates a potential mechanism for the suggested link of sub-optimal Se status with neurodegenerative disease \[[@B49-nutrients-11-00935]\].

Supporting the data presented here, *GPX1* and *GPX4* selenoprotein gene loci have been implicated in GWAS of inflammatory bowel disease (IBD), which is a risk factor for CRC development \[[@B50-nutrients-11-00935],[@B51-nutrients-11-00935]\]. Additionally, the rs7901303 variant from the selenophosphate synthetase 1 (*SEPHS1*) gene, which plays a major role in selenoprotein synthesis, was associated in this study with CRC risk (before multiple testing corrections). rs7901303 was previously associated with risk of Crohn's disease in interaction with serum Se levels in a sub-optimal Se population of New Zealand \[[@B52-nutrients-11-00935]\]. The genetic associations identified in these studies suggest therefore a key role of the corresponding proteins in colorectal function and/or the carcinogenic process.

Genomic studies and animal models have shown Se intake to not only affect expression of selenoprotein genes but also pathways key to colorectal carcinogenesis such as the antioxidant response, immune and inflammatory pathways (including NFkB and Nrf2 signaling) and the Wnt signaling pathway \[[@B4-nutrients-11-00935],[@B13-nutrients-11-00935],[@B53-nutrients-11-00935]\]. Furthermore, expression of constituents of these metabolic pathways has been shown to be affected by Se level in human rectal biopsies \[[@B54-nutrients-11-00935]\]. Therefore, in addition to a focus on Se metabolism and selenoprotein genes, the present analysis also encompassed a substantial examination of genetic variations in these selenium-relevant pathways. Associations of multiple SNPs in the same gene (several of which are novel) with CRC risk were observed in genes from pathways 2--8, e.g., *BAX, GPX5, FOXO3, IL12B, TLR4, MSH2, MSH3, TGFB1*, as well as *IL10* with rectal cancer risk. Polymorphisms in several of these genes have previously been associated with CRC risk \[[@B55-nutrients-11-00935],[@B56-nutrients-11-00935],[@B57-nutrients-11-00935],[@B58-nutrients-11-00935],[@B59-nutrients-11-00935],[@B60-nutrients-11-00935],[@B61-nutrients-11-00935],[@B62-nutrients-11-00935]\]. After BH multiple testing corrections, SNPs in cell-signaling pathways retained significance (*FRZB*, *SMAD3*, and *SMAD7*). The variants in both *SMAD* genes were previously linked to CRC by GWAS, suggesting a role of these variants in CRC development \[[@B38-nutrients-11-00935]\]. The association of rs17265803 in *FRZB* appears to be novel and it is not in LD with the functional *FRZB* genetic variant Arg324Gly (rs7775) previously reported to be associated with an increased CRC risk \[[@B63-nutrients-11-00935]\], although this was not replicated in a nested case-control study \[[@B64-nutrients-11-00935]\]. Additional genetic variants retaining significance by *P*~ACT~ were rs6983267 in *C-MYC* previously identified in a meta-GWAS \[[@B65-nutrients-11-00935]\], rs235770 in *BMP2* previously associated with colon cancer risk \[[@B37-nutrients-11-00935]\], and a novel association of rs4645887 in *BAX*.

In the pathway analysis, all the Se pathway genes were grouped into a primary best-known functional pathway and were analyzed for the association of whole gene and whole pathway genetic variation with CRC risk, and in interaction with Se status. Neither gene only variation or interactions with Se status in the core pathway 1 selenoprotein and biosynthesis pathway were associated with CRC risk by pathway, although gene only variation for *GPX1*, *SELENOM*, *SELENON*, and *SEPHS1* plus gene x Se status interactions for *SELENON* (with SELENOP) and *PSTK* (with Se) were associated with CRC risk. In the gene x Se analysis, only pathway 2 (antioxidant/redox) was significant for an association with CRC risk for both Se and SELENOP. Alternatively, it also remains possible that the genetic 'noise' from any irrelevant selenoproteins masked the overall risk associations for pathway 1 (based on the rationale that most genes in pathways like oxidative stress are important in cancer prevention but that some of the selenoproteins may be irrelevant to colorectal carcinogenesis, as they are included solely because they share selenocysteine motifs). This is partly supported by the strongest association (by PIGE) in pathway 1 for gene variance in *GPX1*, which has been previously implicated in risk of various cancers \[[@B4-nutrients-11-00935]\]. However, these pathway divisions cannot reflect, for example, the biological overlaps with the antioxidant selenoprotein genes in pathway 1 and their non-Se containing counterparts in pathway 2. Several aspects of our data suggest a potentially under-appreciated focus on variation in apoptosis genes (pathway 4) and CRC risk that may also be modified by Se status. These comprise the association of several SNPs in both the *FOXO3* and *BAX* genes (including the *P*~ACT~ significant rs4645887 variant in *BAX*) with CRC risk, significance of *FOXO3* for overall gene variation, and several significant findings of SNP x Se and gene x Se status interactions for genes in this pathway (e.g., *SMAC*, *CASP8*, *MAPK8*, and *MAPK9*). Overall, our analyses suggest that genetic variation in TGF beta signaling (pathway 7), which includes members such as *BMP2*, *BMPR2*, *SMAD3*, and *SMAD7* implicated in CRC risk by previous large case-control and GWAS reports \[[@B36-nutrients-11-00935],[@B37-nutrients-11-00935],[@B38-nutrients-11-00935]\], is sufficient to alter CRC risk, independent of Se status interaction, while SNP risk associations attributed to the antioxidant and apoptosis pathways may be significantly modified by Se status interactions.

Strengths and weaknesses of our study design for the Se status analyses have been discussed earlier \[[@B5-nutrients-11-00935]\]. The hypothesis-driven approach and appreciable sample size within a large, prospective study allowed an extensive examination of Se pathway genetic variation (including gene pathway analyses) and the interaction with robust markers of Se status regarding CRC risk. Despite the large sample size, gene pathway, gene--Se interaction analysis and some stratified analyses had limited power, particularly analyses by sex and anatomical sub-sites. The pathway designations were assigned based on known function from the literature, and there will be interactions between these pathways that we were not able to model. Finally, as most of the reported associations involve tagSNPs of no known functionality (or the actual contributing functional variant(s) they tag) additional genetic mapping and lab-based studies will be needed to explore these aspects.

5. Conclusions {#sec5-nutrients-11-00935}
==============

In summary, the present study indicates that genetic variation in selenoprotein genes and genes in antioxidant/redox, Wnt, apoptotic, and TGF-beta signaling pathways may modify risk of CRC development. Furthermore, for genes in antioxidant/redox and apoptotic pathways the influence of SNPs on the disease risk is also dependent on interaction with Se status. Overall, these results taken together with our previous study \[[@B5-nutrients-11-00935]\] suggest that risk of CRC may be modified by genotype, Se status, sex, and gene variation interactions within biological pathways. Thus, will individuals harboring these genotypes benefit from increased Se intake, including consideration of 'Se adequate' environments, such as the US, where Se intervention trials have not shown a significant benefit in the general population \[[@B66-nutrients-11-00935]\]? Before such a recommendation can be defined, further examination of these findings in other populations and investigation of Se metabolism is needed to clarify the relevance of the Se pathway and signaling genotypes for CRC etio-pathogenesis, especially for individuals with suboptimal Se status.

The following are available online at <https://www.mdpi.com/2072-6643/11/4/935/s1>: Figure S1: Selenium pathway genetic analysis flowchart, Table S1: Se pathway SNP study: List of genes and the 8 pathway designations, the EPIC study, 1992--2003, Table S2: All Se pathway SNPs by gene and pathway and association with CRC risk, the EPIC study, 1992--2003, Table S3: All Se pathway SNPs (by gene and pathway) significantly associated with CRC risk before multiple testing corrections, the EPIC study, 1992--2003, Table S4: Se pathway SNPs from pathways 1--8 associated with Se or SELENOP Concentrations Among Controls, the EPIC study, 1992--2003, Table S5: Se pathway PIGE P values for each gene and CRC risk association per pathway designation, the EPIC study, 1992--2003.
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###### 

Selected baseline characteristics of incident colon and rectal cancer cases and controls, the European Prospective Investigation into Cancer and Nutrition (EPIC) study, 1992--2003.

  Characteristic                           Colon Cancer Cases   Rectal Cancer Cases   Controls                   
  ---------------------------------------- -------------------- --------------------- ---------- -------- ------ --------
  N                                        900                                        520                 1419   
  Women, N (%)                             475                  (52.8)                230        (44.2)   701    (49.4)
  Mean age at blood collection, (SD) yrs   58.8                 (7.5)                 58.0       (6.9)    58.6   (7.4)
  Mean years of follow-up (SD) yrs         4.1                  (2.3)                 4.2        (2.2)           
  Smoking status, N (%) \*                                                                                       
  Never                                    385                  (42.8)                195        (37.5)   594    (41.9)
  Former                                   299                  (33.2)                177        \(34\)   460    (32.4)
  Smoker                                   204                  (22.7)                142        (27.3)   349    (24.6)
  Physical activity, N (%) \*                                                                                    
  Inactive                                 129                  (14.3)                73         \(14\)   183    (12.9)
  Moderately inactive                      257                  (28.6)                145        (27.9)   367    (25.9)
  Moderately active                        374                  (41.6)                209        (40.2)   612    (43.1)
  Active                                   75                   (8.3)                 55         (10.6)   148    (10.4)
  BMI, kg/m^2^, (SD)                       26.9                 (4.36)                26.6       (3.92)   26.3   (3.84)
  Country, N (%)                                                                                                 
  Sweden                                   55                   (6.1)                 33         (6.3)    86     (6.1)
  Denmark                                  174                  (19.3)                164        (31.5)   340    \(24\)
  The Netherlands                          99                   \(11\)                54         (10.4)   158    (11.1)
  United Kingdom                           166                  (18.4)                74         (14.2)   250    (17.6)
  Germany                                  110                  (12.2)                69         (13.3)   169    (11.9)
  France                                   22                   (2.4)                 6          (1.2)    29     \(2\)
  Italy                                    144                  \(16\)                58         (11.2)   198    \(14\)
  Spain                                    101                  (11.2)                45         (8.7)    141    (9.9)
  Greece                                   29                   (3.2)                 17         (3.3)    48     (3.4)

\* Percentages do not add up to 100% due to missing values. Abbreviations: BMI, body mass index; N, sample size; SD, standard deviation; yrs, years.

nutrients-11-00935-t002_Table 2

###### 

Single nucleotide polymorphisms (SNPs) associated with colorectal cancer (CRC) risk in primary selenium pathway 1 (selenium and selenoprotein transport, biosynthesis and metabolism) with raw *P*-values \< 0.01 in at least one genetic model prior to multiple testing adjustment, the EPIC study, 1992--2003.

  Gene/SNP/Genotype             CRC    Control   OR (95% CI)        *P*     *P~BH~^+^*
  ----------------------------- ------ --------- ------------------ ------- ------------
  *GPX1*/rs17080528                                                         
   GG                           700    620       1.00 (ref)         0.010   0.703
   GA                           580    636       0.81 (0.69,0.95)           
   AA                           131    154       0.75 (0.58,0.97)           
   Additive \*                  1411   1410      0.84 (0.75,0.95)   0.003   0.554
   Dominant (GA + AA vs. GG)    1411   1410      0.80 (0.69,0.92)   0.003   0.534
   Recessive (AA vs. GG + GA)   1411   1410      0.83 (0.65,1.06)   0.137   0.854
  *SELENOM*/rs11705137                                                      
   AA                           367    346       1.00 (ref)         0.024   0.753
   AG                           631    648       0.91 (0.75,1.09)           
   GG                           288    359       0.74 (0.60,0.92)           
   Additive \*                  1286   1353      0.86 (0.78,0.96)   0.008   0.684
   Dominant (AG + GG vs. AA)    1286   1353      0.85 (0.71,1.01)   0.064   0.815
   Recessive (GG vs. AA + AG)   1286   1353      0.79 (0.66,0.95)   0.012   0.710
  *SELENON*/rs4659382                                                       
   GG                           783    713       1.00 (ref)         0.019   0.747
   GC                           509    573       0.80 (0.69,0.94)           
   CC                           96     107       0.82 (0.61,1.10)           
   Additive \*                  1388   1393      0.86 (0.76,0.97)   0.011   0.710
   Dominant (GC + CC vs. GG)    1388   1393      0.81 (0.69,0.94)   0.005   0.625
   Recessive (CC vs. GG + GC)   1388   1393      0.90 (0.67,1.20)   0.455   0.954
  *SEPHS1*/rs2275129                                                        
   GG                           361    423       1.00 (ref)         0.032   0.780
   GC                           726    690       1.23 (1.03,1.47)           
   CC                           321    295       1.28 (1.04,1.58)           
   Additive \*                  1408   1408      1.14 (1.02,1.26)   0.017   0.747
   Dominant (GC + CC vs. GG)    1408   1408      1.25 (1.05,1.47)   0.010   0.697
   Recessive (CC vs. GG + GC)   1408   1408      1.12 (0.94,1.34)   0.217   0.885
  *TXNRD1*/rs11111979 ^\^^                                                  
   GG                           395    429       1.00 (ref)         0.015   0.745
   GC                           627    680       1.00 (0.84,1.20)           
   CC                           279    230       1.34 (1.07,1.67)           
   Additive \*                  1301   1339      1.14 (1.02,1.27)   0.022   0.749
   Dominant (GC + CC vs. GG)    1301   1339      1.09 (0.92,1.28)   0.315   0.932
   Recessive (CC vs. GG + GC)   1301   1339      1.33 (1.10,1.62)   0.004   0.566

^+^ = After Benjamini--Hochberg (BH) multiple testing correction; \* = Additive models impose a structure in which each additional copy of the variant allele increases the response (log odds ratio) by the same amount; \^ = *TXNRD1* rs11111979 was borderline significant after adjustment for correlated tests (*P~ACT~* = 0.10). EPIC = European Prospective Investigation into Cancer and Nutrition.
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###### 

Single Nucleotide Polymorphisms (SNPs) statistically significantly associated with colorectal cancer (CRC) risk after Benjamini--Hochberg (BH) multiple testing correction, the EPIC study, 1992--2003.

  Gene/SNP/Genotype             CRC    Control   OR (95% CI)        *P*        *P~BH~*
  ----------------------------- ------ --------- ------------------ ---------- ----------
  *FRZB*/rs17265803 \^                                                         
   AA                           844    976       1.00 (ref)         3.04E-06   0.003
   AG                           315    240       1.56 (1.28,1.89)              
   Additive \*                  1163   1232      1.35 (1.13,1.62)   0.001      0.372
   Dominant (AG + GG vs. AA)    1163   1232      1.48 (1.22,1.79)   6.77E-05   0.034
   Recessive (GG vs. AA + AG)   1163   1232      0.26 (0.09,0.80)   0.018      0.747
  *SMAD3*/rs7180244 \^                                                         
   GG                           994    1183      1.00 (ref)         2.22E-16   1.12E-12
   GC                           372    198       2.33 (1.92,2.83)              
   Additive \*                  1372   1388      2.16 (1.79,2.60)   1.11E-15   3.74E-12
   Dominant (GC + CC vs. GG)    1372   1388      2.28 (1.88,2.77)   1.11E-16   1.12E-12
   Recessive (CC vs. GG + GC)   1372   1388      0.87 (0.29,2.61)   0.804      0.997
  *SMAD7*/rs11874392                                                           
   AA                           478    400       1.00 (ref)         1.39E-07   2.82E-04
   AT                           704    671       0.88 (0.74,1.04)              
   TT                           222    337       0.55 (0.44,0.68)              
   Additive \*                  1404   1408      0.75 (0.68,0.84)   1.99E-07   3.36E-04
   Dominant (AT + TT vs. AA)    1404   1408      0.77 (0.65,0.90)   0.001      0.372
   Recessive (TT vs. AA + AT)   1404   1408      0.59 (0.49,0.72)   6.26E-08   1.58E-04
  *SMAD7*/rs12953717                                                           
   GG                           366    470       1.00 (ref)         3.47E-05   0.019
   GA                           671    643       1.36 (1.14,1.62)              
   AA                           335    273       1.60 (1.29,1.98)              
   Additive \*                  1372   1386      1.27 (1.14,1.41)   9.07E-06   0.006
   Dominant (GA + AA vs. GG)    1372   1386      1.43 (1.21,1.68)   2.38E-05   0.014
   Recessive (AA vs. GG + GA)   1372   1386      1.32 (1.10,1.59)   0.003      0.534
  *SMAD7*/rs4939827                                                            
   AA                           433    378       1.00 (ref)         6.46E-06   0.005
   AG                           664    634       0.92 (0.77,1.09)              
   GG                           248    357       0.60 (0.49,0.75)              
   Additive \*                  1345   1369      0.79 (0.71,0.87)   9.46E-06   0.006
   Dominant (AG + GG vs. AA)    1345   1369      0.80 (0.68,0.95)   0.009      0.697
   Recessive (GG vs. AA + AG)   1345   1369      0.64 (0.53,0.77)   1.66E-06   0.002
  *SMAD7*/rs6507874                                                            
   AA                           467    389       1.00 (ref)         1.93E-06   0.002
   AG                           705    677       0.87 (0.73,1.03)              
   GG                           234    336       0.57 (0.46,0.71)              
   Additive \*                  1406   1402      0.77 (0.69,0.86)   1.26E-06   0.002
   Dominant (AG + GG vs. AA)    1406   1402      0.77 (0.65,0.90)   0.001      0.420
   Recessive (GG vs. AA + AG)   1406   1402      0.63 (0.52,0.76)   1.16E-06   0.002

\^ = Results for the rare homozygous genotypes are omitted for these SNPs due to the small sample numbers with these genotypes; \* = Additive models impose a structure in which each additional copy of the variant allele increases the response (log odds ratio) by the same amount. EPIC = European Prospective Investigation into Cancer and Nutrition.
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###### 

*P*-values for genetic pathways and pathway-selenium (Se) status interactions and colorectal cancer risk, the EPIC study, 1992--2003.

  Pathway                    *P* ~Pathway\ Only~   *P* ~Pathway\ Only\ (non-Missing\ Se\ Status)~ ^\*\*\*^   *P* ~Pathway\ x\ Se\ Interaction~   *P* ~Pathway\ x\ SELENOP\ Interaction~
  -------------------------- --------------------- --------------------------------------------------------- ----------------------------------- ----------------------------------------
  Se and Selenoproteins \*   0.217                 0.098                                                     0.615                               0.726
  Antioxidant and Redox      0.173                 0.072                                                     0.011                               0.010
  Cell signaling \*\*        0.307                 0.489                                                     0.223                               0.872
  Apoptosis                  0.361                 0.097                                                     0.003                               0.105
  Inflammation               0.822                 0.262                                                     0.199                               0.607
  DNA repair                 0.739                 0.432                                                     0.175                               0.088
  TGFβ signaling             \<0.001               0.001                                                     0.061                               0.764
  Cell cycle control         0.398                 0.475                                                     0.097                               0.449

\* Se and selenoprotein transport, biosynthesis & metabolism. \*\* Includes Wnt, mTOR, NfkB, and Nrf2 signaling. \*\*\* Includes only participants with non-missing blood Se or SELENOP concentrations. EPIC = European Prospective Investigation into Cancer and Nutrition.
